Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs

CONCLUSIONS AND RELEVANCE: In this cohort study, new 340B participation was associated with statistically significant higher oncological drug episode spending compared with nonparticipants after changes in 340B inclusion rules in 2010. These findings raise questions about unintended consequences of the 340B program on drug spending from the commercially insured population.PMID:37351874 | DOI:10.1001/jamahealthforum.2023.1485

Source: Cancer Control - June 23, 2023 Category: Cancer & Oncology Authors: Jessica Chang Pinar Karaca-Mandic Sayeh Nikpay Molly Moore Jeffery Source Type: research